|
1
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kollarova H, Machova L, Horakova D,
Janoutova G and Janout V: Epidemiology of esophageal cancer - an
overview article. Biomed Pap Med Fac Univ Palacky Olomouc Czech
Repub. 151:17–20. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rubin CI and Atweh GF: The role of
stathmin in the regulation of the cell cycle. J Cell Biochem.
93:242–250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tian FJ, Qin CM, Li XC, Wu F, Liu XR, Xu
WM and Lin Y: Decreased stathmin-1 expression inhibits trophoblast
proliferation and invasion and is associated with recurrent
miscarriage. Am J Pathol. 185:2709–2721. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Machado-Neto JA, Saad STO and Traina F:
Stathmin 1 in normal and malignant hematopoiesis. BMB Rep.
47:660–665. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rana S, Maples PB, Senzer N and Nemunaitis
J: Stathmin 1: A novel therapeutic target for anticancer activity.
Expert Rev Anticancer Ther. 8:1461–1470. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei SH, Lin F, Wang X, Gao P and Zhang HZ:
Prognostic significance of stathmin expression in correlation with
metastasis and clinicopathological characteristics in human ovarian
carcinoma. Acta Histochem. 110:59–65. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ghosh R, Gu G, Tillman E, Yuan J, Wang Y,
Fazli L, Rennie PS and Kasper S: Increased expression and
differential phosphorylation of stathmin may promote prostate
cancer progression. Prostate. 67:1038–1052. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baquero MT, Hanna JA, Neumeister V, Cheng
H, Molinaro AM, Harris LN and Rimm DL: Stathmin expression and its
relationship to microtubule-associated protein tau and outcome in
breast cancer. Cancer. 118:4660–4669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma HL, Jin SF, Tao WJ, Zhang ML and Zhang
ZY: Overexpression of stathmin/oncoprotein 18 correlates with
poorer prognosis and interacts with p53 in oral squamous cell
carcinoma. J Craniomaxillofac Surg. 44:1725–1732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gan L, Guo K, Li Y, Kang X, Sun L, Shu H
and Liu Y: Upregulated expression of stathmin may be associated
with hepatocarcinogenesis. Oncol Rep. 23:1037–1043. 2010.PubMed/NCBI
|
|
13
|
Zhang HZ, Gao P, Yan L and Lin F:
Significance of stathmin gene overexpression in osteosarcoma cells.
Ai Zheng. 23:493–496. 2004.(In Chinese). PubMed/NCBI
|
|
14
|
Sun R, Liu Z, Wang L, Lv W, Liu J, Ding C,
Yuan Y, Lei G and Xu C: Overexpression of stathmin is resistant to
paclitaxel treatment in patients with non-small cell lung cancer.
Tumour Biol. 36:7195–7204. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nie W, Xu MD, Gan L, Huang H, Xiu Q and Li
B: Overexpression of stathmin 1 is a poor prognostic biomarker in
non-small cell lung cancer. Lab Invest. 95:56–64. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang F, Wang LX, He W, Zhu LN, Zhao PR and
Fan QX: Expression of stathmin in esophageal squamous cell
carcinoma and its biological significance. Nan Fang Yi Ke Da Xue
Xue Bao. 30:1552–1557. 2010.(In Chinese). PubMed/NCBI
|
|
17
|
Akhtar J, Wang Z, Jiang WP, Bi MM and
Zhang ZP: Stathmin overexpression identifies high risk for
lymphatic metastatic recurrence in pN0 esophageal squamous
cell carcinoma patients. J Gastroenterol Hepatol. 29:944–950. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rice TW, Blackstone EH and Rusch VW: 7th
edition of the AJCC Cancer Staging Manual: Esophagus and
esophagogastric junction. Ann Surg Oncol. 17:1721–1724. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fléjou JF: WHO Classification of Digestive
Tumors: 4th edition. Ann Pathol. 31 Suppl 5:S27–S31. 2011.(In
French). View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xie JJ, Xu LY, Wu ZY, Zhao Q, Xu XE, Wu
JY, Huang Q and Li EM: Prognostic implication of ezrin expression
in esophageal squamous cell carcinoma. J Surg Oncol. 104:538–543.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun LL, Holowatyj A, Xu XE, Wu JY, Wu ZY,
Shen JH, Wang SH, Li EM, Yang ZQ and Xu LY: Histone demethylase
GASC1, a potential prognostic and predictive marker in esophageal
squamous cell carcinoma. Am J Cancer Res. 3:509–517.
2013.PubMed/NCBI
|
|
22
|
Xie JJ, Zhang FR, Tao LH, Lü Z, Xu XE,
Jian S, Xu LY and Li EM: Expression of ezrin in human embryonic,
fetal, and normal adult tissues. J Histochem Cytochem.
59:1001–1008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie JJ, Xu LY, Wu JY, Shen ZY, Zhao Q, Du
ZP, Lv Z, Gu W, Pan F, Xu XE, et al: Involvement of CYR61
and CTGF in the fascin-mediated proliferation and
invasiveness of esophageal squamous cell carcinomas cells. Am J
Pathol. 176:939–951. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kuang XY, Chen L, Zhang ZJ, Liu YR, Zheng
YZ, Ling H, Qiao F, Li S, Hu X and Shao ZM: Stathmin and
phospho-stathmin protein signature is associated with survival
outcomes of breast cancer patients. Oncotarget. 6:22227–22238.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu Y, Liu C, Cheng H, Xu Y, Jiang J, Xu J,
Long J, Liu L and Yu X: Stathmin, interacting with Nf-κB, promotes
tumor growth and predicts poor prognosis of pancreatic cancer. Curr
Mol Med. 14:328–339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ke B, Wu LL, Liu N, Zhang RP, Wang CL and
Liang H: Overexpression of stathmin 1 is associated with poor
prognosis of patients with gastric cancer. Tumour Biol.
34:3137–3145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hsieh SY, Huang SF, Yu MC, Yeh TS, Chen
TC, Lin YJ, Chang CJ, Sung CM, Lee YL and Hsu CY: Stathmin1
overexpression associated with polyploidy, tumor-cell invasion,
early recurrence, and poor prognosis in human hepatoma. Mol
Carcinog. 49:476–487. 2010.PubMed/NCBI
|
|
28
|
Sherbet GV and Cajone F: Stathmin in cell
proliferation and cancer progression. Cancer Genomics Proteomics.
2:227–237. 2005.
|
|
29
|
Li X, Wang L, Li T, You B, Shan Y, Shi S,
Qian L and Cao X: STMN1 overexpression correlates with biological
behavior in human cutaneous squamous cell carcinoma. Pathol Res
Pract. 211:816–823. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li J, Hu G, Kong F, Wu K, Song K, He J and
Sun W: Elevated STMN1 expression correlates with poor prognosis in
patients with pancreatic ductal adenocarcinoma. Pathol Oncol Res.
21:1013–1020. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu F, Sun YL, Xu Y, Liu F, Wang LS and
Zhao XH: Expression and phosphorylation of stathmin correlate with
cell migration in esophageal squamous cell carcinoma. Oncol Rep.
29:419–424. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen Y, Zhang Q, Ding C, Zhang X, Qiu X
and Zhang Z: Stathmin1 overexpression in hypopharyngeal squamous
cell carcinoma: A new promoter in FaDu cell proliferation and
migration. Int J Oncol. 50:31–40. 2017. View Article : Google Scholar : PubMed/NCBI
|
